Sempra Energy SRE, an energy services holding company, engages in the sale, distribution, storage and transportation of electricity and natural gas.
Sempra Energy’s stable cash generating capacity, several development projects, steady focus on expansion of renewable capacity and strategic acquisitions is expected to boost its future performance.
Sempra Energy Price and EPS Surprise
Sempra Energy Price and EPS Surprise | Sempra Energy Quote
Estimate Trend & Surprise History
Investors should note that the recent earnings estimate for Sempra Energy of $1.47 has improved by 1.38% over the past 60 days.
Coming to the earnings surprise history, Sempra Energy has surpassed the Zacks Consensus Estimate in three out of the last four quarters with an average positive beat of 4.97%.
Going further things could definitely change given the company’s recently released earnings results.
Zacks Rank: The company currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change.
Going below we have mentioned some of the vital information from this just-revealed announcement:
Earnings: Sempra Energy’s earnings in fourth quarter surpassed expectation. Our consensus called for fourth-quarter EPS of $1.47, while the company reported adjusted EPS of $1.56. The company also surpassed year ago earnings by 1.3%.
Revenues: The company exceeded the revenue expectation as well. Our consensus called for fourth-quarter revenues of $3,183 million, and the company reported revenues of $3,221 million.
Key Note: Total gas sales including delivery in the reported quarter was 227 billion cubic feet down 4.62% year over year.
Check back later for our full write up on this SRE earnings report later!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment